Pure Bioscience Reports Shareholder Vote

Ticker: PURE · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1006028

Pure Bioscience, Inc. 8-K Filing Summary
FieldDetail
CompanyPure Bioscience, Inc. (PURE)
Form Type8-K
Filed DateJan 28, 2025
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

TL;DR

PURE had a shareholder vote on Jan 22nd, details TBD.

AI Summary

Pure Bioscience, Inc. filed an 8-K on January 28, 2025, reporting on a matter submitted to a vote of its security holders on January 22, 2025. The filing does not disclose the specific outcome or details of the vote, only that it occurred.

Why It Matters

Shareholder votes can signal significant corporate decisions or changes in governance, impacting investor confidence and future company direction.

Risk Assessment

Risk Level: low — This filing is procedural and does not contain new financial or operational information that would immediately impact the company's risk profile.

Key Players & Entities

  • PURE BIOSCIENCE, INC. (company) — Registrant
  • January 22, 2025 (date) — Date of earliest event reported
  • January 28, 2025 (date) — Date of report

FAQ

What was the specific matter submitted to a vote of Pure Bioscience, Inc. security holders on January 22, 2025?

The filing does not specify the exact matter that was put to a vote.

What was the outcome of the shareholder vote on January 22, 2025?

The filing does not disclose the results or outcome of the shareholder vote.

When was this 8-K filing submitted to the SEC?

The filing was submitted on January 28, 2025.

What is the principal executive office address for Pure Bioscience, Inc.?

The address is 771 Jamacha Rd., #512 El Cajon, California 92019.

What is the SIC code for Pure Bioscience, Inc.?

The Standard Industrial Classification code is 2890, for Miscellaneous Chemical Products.

Filing Stats: 725 words · 3 min read · ~2 pages · Grade level 9.7 · Accepted 2025-01-28 16:10:33

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PURE BIOSCIENCE, INC. Dated: January 28, 2025 By: /s/ Robert Bartlett Robert Bartlett Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.